The Pillow Sign: Is It Always Benign?

Sujay Alvencar, MD, Erik Holzwanger, MD, Rohit Dhingra, MD, Raffi Karagozian, MD, Lori Olans, MD, and Nikola S. Natov, MD

Tufts Medical Center, Boston, MA

ABSTRACT

Mucosa-associated lymphoid tissue (MALT) lymphoma is classically found in the stomach; however, in less common, cases can be found in extragastric locations. Colonic MALTomas are exceedingly rare and comprise a small group of extragastric cases. There is no standardized approach for optimal management of this disease. We report a case of a colonic MALT lymphoma found on colonoscopy that demonstrated the pillow sign and appearance of a benign lipoma. Despite antimicrobial and endoscopic therapy, the malignancy reoccurred in a patient with chronic hepatitis B, thereby precluding one of the mainstays of treatment, rituximab, until viral eradication.

INTRODUCTION

Extranodal marginal zone lymphoma, also known as low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), is an indolent form of non-Hodgkin lymphoma that comprises approximately 5%-10% of all non-Hodgkin lymphoma.1,2 These lymphomas tend to occur in the setting of chronic immune activation, including autoimmune or infectious etiologies such as Sjogren, systemic lupus erythematosus, Helicobacter pylori, Campylobacter jejuni, hepatitis B (HBV), and hepatitis C (HCV).3,4 MALT lymphomas classically originate in the stomach, with less common occurrences in extragastric locations. Primary extranodal marginal zone lymphoma of the large intestine occurs infrequently.2 As a result, there is no standardized approach for the treatment of colonic MALT lymphomas when compared with their gastric counterparts.2,5 We report a case of a colonic MALT lymphoma incidentally found on biopsy obtained during colonoscopy and the complexity of treatment in the setting of chronic HBV.

CASE REPORT

A 56-year-old man from China with a history of untreated chronic HBV (HBV surface antigen-positive, HBV e-antigen negative, HBV e-antibody positive) presented to his primary care physician with 1 month of unintentional 10-pound weight loss and worsening fatigue. He denied abdominal pain, nausea, vomiting, diarrhea, constipation, hematochezia, melena, night sweats, or fevers. There was no family history of gastrointestinal malignancy. He had a 30 pack-year smoking history and consumed several beers per day. Liver function tests were notable for aspartate aminotransferase 44 IU/L, alanine aminotransferase 50 IU/L, alkaline phosphatase 88 IU/L, lactate dehydrogenase 368 IU/L, and total bilirubin 0.8 mg/dL. An abdominal ultrasound revealed cholelithiasis.

A colonoscopic evaluation revealed a 6-mm subepithelial lesion at the hepatic flexure with a positive pillow sign (Figure 1). Biopsies of the lesion were obtained by tunnel biopsy with jumbo cold forceps, which returned diagnostic for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with immunochemical staining positive for PAX5, CD20, CD43, BCL2, and MUM1 while negative for CD5, CD10, CD23, BCL6, CD30, and Cyclin D1 (Figure 2). Esophagogastroduodenoscopy was grossly unrevealing; however, biopsies of the antrum and body returned positive for H. pylori-associated chronic active gastritis without dysplasia. H. pylori stool antigen was also positive, and the patient was treated with clarithromycin, amoxicillin, and omeprazole with eradication of H. pylori confirmed...
through negative stool antigen. Thoracic, abdominal, and pelvic computed tomography for staging did not demonstrate metastatic lesions. Positron emission tomography scan showed reactive cervical lymph nodes but no metastatic disease.

After a multidisciplinary discussion, the decision was made to proceed with endoscopic mucosal resection given the lack of metastatic disease and the desire to avoid rituximab in the setting of chronic HBV. The patient underwent a repeat colonoscopy with en bloc injection-assisted endoscopic mucosal resection of the colonic MALT lymphoma. The resection edge was treated with snare tip soft coagulation current to decrease the risk of recurrence and closed with hemostatic clips. Surveillance colonoscopy 6 months later showed no obvious recurrence, but biopsies of the mucosectomy scar were diagnostic of persistent MALT lymphoma (Figure 3). As a result, he is currently undergoing further evaluation of treatment for his chronic HBV for possible initiation of rituximab.

DISCUSSION

The endoscopic pillow sign refers to the creation of a surface indentation made by pressing the tip of a cold forceps onto a subepithelial lesion. In most cases, the pillow sign has been associated with benign lipomas. It is argued that conventional biopsies of these lesions are of little utility because they are superficial, limited to the surface mucosa, and rarely diagnostic. Therefore, most of these lesions are not biopsied and managed expectantly. Although colonic MALT lymphomas are rare, this is the first case to the best of our knowledge presenting as a lesion exhibiting the pillow sign.

The management of colonic MALT lymphomas is highly debated. Because of the low incidence of the disease, a standardized approach has been difficult to establish. Management ranges from H. pylori eradication, chemotherapy, radiotherapy, immune therapy with rituximab, endoscopic mucosal resection, and/or surgery. Eradication therapy for H. pylori has had variable outcomes for colonic MALT lymphomas. There is less correlation between H. pylori and primary colonic MALT lymphomas, when compared with gastric MALT lymphomas. A limited number of case reports have demonstrated colonic MALT lymphoma regression with H. pylori eradication treatment. However, several studies suggest that H. pylori treatment is ineffective in non-gastric MALT lymphomas with such patients often resorting to surgery or chemotherapy.

Radiotherapy has become less appealing for treating colonic MALT lymphoma because of potential adverse intestinal effects. The mainstay of chemotherapy consists of alkylating agents. In retrospective studies, recurrence has been low for patients who underwent chemotherapy alone. Because of toxicities associated with chemotherapy, it is commonly used for patients with extensive disease. More recently, immune therapy with rituximab has been used with some success and
which initial intervention to pursue.\textsuperscript{15,16} ACG Case Reports Journal / Volume 8 acgcasereports.com 3

demonstrates a favorable side-effect profile when compared with most alkylating agents.\textsuperscript{2,13} However, rituximab alone, without endoscopic or surgical resection, has been unsuccessful in achieving remission in limited cases.\textsuperscript{13} In addition, immune therapy increases the reactivation risk of chronic viral and bacterial conditions and should be used with caution in this setting, as with the case presented.

Endoscopic and surgical resection provide more definitive treatment options.\textsuperscript{10} Most reported cases of colonic MALT lymphoma document localized disease, as opposed to metastatic disease, at the time of diagnosis. Many reports demonstrate no recurrence after endoscopic or surgical resection.\textsuperscript{10,14} There have been no prospective studies comparing recurrence after endoscopic vs surgical resection, likely because of the limited case numbers. Endoscopic ultrasound, which can evaluate for signs of invasion, may be of benefit in deciding which initial intervention to pursue.\textsuperscript{15,16}

This case describes an unusual presentation of a rare entity, colonic MALT lymphoma, and highlights the complexities of treating this disease. The differential diagnosis for lesions exhibiting the pillow sign should not be limited to benign etiologies alone. Colonic MALT lymphoma should be considered as well. In our case, despite \textit{H. pylori} eradication and endoscopic mucosal resection, disease recurrence occurred. Many questions remain unanswered concerning colonic MALT lymphoma, and more research is needed to devise a treatment algorithm that can assist with maintaining remission.

DISCLOSURES

Author contributions: All authors contributed equally to this manuscript. S. Alvencar is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received June 8, 2020; Accepted September 4, 2020

REFERENCES

1. Dolce Manson S. Mucosa-associated lymphoid tissue (MALT) lymphoma. \textit{Semin Oncol}. 2006;22(1):73–9.
2. Abbas H, Niazi M, Makker J. Mucosa-associated lymphoid tissue (MALT) lymphoma of the colon: A case report and a literature review. \textit{Am J Case Rep}. 2017;18(1):491–7.
3. Raderer M, Kieszewetter B, Ferreri AJM. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). \textit{CA Cancer J Clin}. 2016;66:152–71.
4. Ulcickas Yood M, Quesenberry CP Jr, Guo D, et al. Incidence of non-Hodgkin’s lymphoma among individuals with chronic hepatitis B virus infection. \textit{Hepatology}. 2007;46:107–12.
5. Toquero I, Aboumarzouk OM, Lanzon-Miller S. Colonic MALT lymphoma: A case report and review of the literature. \textit{BMJ Case Rep}. 2009;2009:bc01.2009.1537.
6. Mummadi R, Raju GS. New endoscopic approaches to removing colonic lipomas. \textit{Gastroenterol Hepatol}. 2007;3(11):882–3.
7. Hwang JH, Kimmey MB. The incidental upper gastrointestinal subepithelial mass. \textit{Gastroenterology}. 2004;126(1):301–7.
8. Matsu S, Mizuta Y, Hayashi T, et al. Mucosa-associated lymphoid tissue lymphoma of the transverse colon: A case report. \textit{World J Gastroenterol}. 2006;12(34):5573–6.
9. Grünberger B, Wohrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric malt lymphoma. \textit{J Clin Oncol}. 2006;24:1370–5.
10. Akasaka R, Chiba T, Dutta AK, et al. Colonic mucosa-associated lymphoid tissue lymphoma. \textit{Case Rep Gastroenterol}. 2012;6(2):569–75.
11. Matsyiak-Budnik T, Fabiani B, Henequin C, et al. Gastrointestinal lymphomas: French intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SFEGE, FFCD, GERCOR, UNICANCER, SFCD, SED, SFRO, SFH). \textit{Dig Liver Dis}. 2018;50(2):124–31.
12. Tannoury J, Amiot A, Lemonnier F, et al. Colonic mucosa-associated lymphoid tissue lymphoma: A case series. \textit{Leuk Lymphoma}. 2020;61(3):582–7.
13. Jeon MK, So H, Huh J, et al. Endoscopic features and clinical outcomes of colorectal mucosa-associated lymphoid tissue lymphoma. \textit{Gastrointest Endosc}. 2018;87(2):529–39.
14. Ghiemire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. \textit{World J Gastroenterol}. 2011;17(6):697–707.
15. Yoshimura D, Maruoka A, Maekawa S, Yao T, Harada N, Nawata H. Transverse colon MALT lymphoma with nodal metastasis. \textit{Gastrointest Endosc}. 2002;55(2):238–9.
16. Esteban JM, Gutiérrez del Olmo A, Baki W, et al. Colonic mucosa-associated lymphoid tissue lymphoma presenting as multiple polyposis. \textit{Gastrointest Endosc}. 2005;61(7):928–30.